Dipeptidyl peptidase-4 inhibitors have shown potential bone-protective effects in experimental models, but clinical evidence in patients with type 2 diabetes remains limited. To address this gap, a study evaluated the efficacy and safety of oral sitagliptin treatment on bone outcomes in 132 women with type 2 diabetes . The study found that sitagliptin preserved total proximal femur bone mineral density compared with placebo in women with type 2 diabetes , with minimal change from baseline (−0.02) versus a significant decline with placebo (−0.13), resulting in a significant between-group difference of 0.11.
No significant differences were observed at other skeletal sites or in bone turnover markers. Sitagliptin significantly reduced inflammatory mediators involved in bone metabolism, showed no differences in glycemic control, and was well tolerated with no serious adverse events. These…
